Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
140 hedge funds and large institutions have $1.16B invested in Clovis Oncology, Inc. in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 58 increasing their positions, 44 reducing their positions, and 21 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
2% more funds holding
Funds holding: 137 → 140 (+3)
33% less call options, than puts
Call options by funds: $22.1M | Put options by funds: $33M
38% less capital invested
Capital invested by funds: $1.87B → $1.16B (-$711M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$37.5M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$23.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.6M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$18.2M |
| 5 |
O
OppenheimerFunds
New York
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$32.9M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$32.6M |
| 3 |
VAM
Visium Asset Management
New York
|
-$19M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.2M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$13.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
151
DAFNA Capital Management
Los Angeles,
California
| – | -$873K | -12,600 | Closed |
|
|
SCM
152
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$425K | -6,134 | Closed |
|
|
HI
153
HBK Investments
Dallas,
Texas
| – | -$423K | -6,100 | Closed |
|
|
QIM
154
Quantitative Investment Management
Charlottesville,
Virginia
| – | -$374K | -5,400 | Closed |
|
|
ST
155
Spot Trading
Chicago,
Illinois
| – | -$167K | -3,233 | Closed |
|
156
Credit Agricole
Montrouge Cedex,
France
| – | -$159K | -2,300 | Closed |
|
|
PG
157
PEAK6 Group
Chicago,
Illinois
| – | -$121K | -1,750 | Closed |
|
|
BJ
158
BlackRock Japan
Tokyo,
Japan
| – | -$29K | -413 | Closed |
|
|
SFPIA
159
Stevens First Principles Investment Advisors
Newport Beach,
California
| – | -$28K | -400 | Closed |
|
|
WA
160
WFG Advisors
Dallas,
Texas
| – | -$6K | -92 | Closed |
|
|
AF
161
Arrow Financial
Glens Falls,
New York
| – | -$5K | -70 | Closed |
|
CLVS Hedge Fund Activity: Q2 2014 in Review
140 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2014, worth a combined $1.16B — down 38% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CLVS positions and 21 closed out — a net gain of 3 holders — while 58 added to existing stakes and 44 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $37.5M. The largest seller was HealthCor Management, exiting entirely with an estimated $32.9M sold.
- 140 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2014, up from 137 in Q1 2014.
- Funds reported $1.16B of Clovis Oncology, Inc. stock for Q2 2014, down 38% quarter-over-quarter.
- 24 funds opened new Clovis Oncology, Inc. positions in Q2 2014 and 21 closed out, a net change of +3 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2014 was Palo Alto Investors, an estimated $37.5M added.
- The largest Clovis Oncology, Inc. seller in Q2 2014 was HealthCor Management, an estimated $32.9M sold.
Based on aggregated 13F filings for Q2 2014.